Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy

Brittany L. Murphy, Alexandra B. Gonzalez, Amy L. Conners, Tara L. Henrichsen, Michael G. Keeney, Beiyun Chen, Toan T. Nguyen, William S. Harmsen, Elizabeth B Habermann, Harsh N. Shah, James W Jakub

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Objectives: Current randomized controlled trials are investigating the outcomes of non-surgical treatment for patients with ductal carcinoma in situ (DCIS). We sought to evaluate pre-operative factors associated with no residual disease at definitive resection following a core needle biopsy (CNB) diagnosis of DCIS. Methods: Eight hundred and thirty-four operations for DCIS were performed at our institution between January 2004 and October 2014. We evaluated patient and biopsy tumor characteristics to determine pre-operative factors associated with no residual disease at surgical resection using uni- and multivariable analyses. Results: Sixty-nine patients (8%) had no residual disease on final pathology. On multivariable analysis, low- or intermediate-grade lesions, <1 cm in size on mammography, and lesions where ≥90% of calcifications were removed correlated with finding no residual disease on final pathology, c-statistic 0.84. Of the 14 patients with all three low-risk factors, 36% had no residual disease on final pathology. Conclusions: Although our multivariable analysis performed well, its clinical utility would be limited as we were unable to identify a subset of patients with DCIS in whom the probability of finding no residual disease is low enough to consider routine use of non-surgical management.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalJournal of Surgical Oncology
Volume116
Issue number2
DOIs
StatePublished - Aug 1 2017

Fingerprint

Large-Core Needle Biopsy
Carcinoma, Intraductal, Noninfiltrating
Pathology
Mammography
Randomized Controlled Trials
Biopsy
Neoplasms

Keywords

  • core needle biopsy
  • DCIS
  • ductal carcinoma in situ
  • invasive
  • no residual disease
  • progression
  • upstage

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy. / Murphy, Brittany L.; Gonzalez, Alexandra B.; Conners, Amy L.; Henrichsen, Tara L.; Keeney, Michael G.; Chen, Beiyun; Nguyen, Toan T.; Harmsen, William S.; Habermann, Elizabeth B; Shah, Harsh N.; Jakub, James W.

In: Journal of Surgical Oncology, Vol. 116, No. 2, 01.08.2017, p. 213-219.

Research output: Contribution to journalArticle

Murphy, Brittany L. ; Gonzalez, Alexandra B. ; Conners, Amy L. ; Henrichsen, Tara L. ; Keeney, Michael G. ; Chen, Beiyun ; Nguyen, Toan T. ; Harmsen, William S. ; Habermann, Elizabeth B ; Shah, Harsh N. ; Jakub, James W. / Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy. In: Journal of Surgical Oncology. 2017 ; Vol. 116, No. 2. pp. 213-219.
@article{a0da43cf4d7b452597b4706c34e7e1e6,
title = "Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy",
abstract = "Background and Objectives: Current randomized controlled trials are investigating the outcomes of non-surgical treatment for patients with ductal carcinoma in situ (DCIS). We sought to evaluate pre-operative factors associated with no residual disease at definitive resection following a core needle biopsy (CNB) diagnosis of DCIS. Methods: Eight hundred and thirty-four operations for DCIS were performed at our institution between January 2004 and October 2014. We evaluated patient and biopsy tumor characteristics to determine pre-operative factors associated with no residual disease at surgical resection using uni- and multivariable analyses. Results: Sixty-nine patients (8{\%}) had no residual disease on final pathology. On multivariable analysis, low- or intermediate-grade lesions, <1 cm in size on mammography, and lesions where ≥90{\%} of calcifications were removed correlated with finding no residual disease on final pathology, c-statistic 0.84. Of the 14 patients with all three low-risk factors, 36{\%} had no residual disease on final pathology. Conclusions: Although our multivariable analysis performed well, its clinical utility would be limited as we were unable to identify a subset of patients with DCIS in whom the probability of finding no residual disease is low enough to consider routine use of non-surgical management.",
keywords = "core needle biopsy, DCIS, ductal carcinoma in situ, invasive, no residual disease, progression, upstage",
author = "Murphy, {Brittany L.} and Gonzalez, {Alexandra B.} and Conners, {Amy L.} and Henrichsen, {Tara L.} and Keeney, {Michael G.} and Beiyun Chen and Nguyen, {Toan T.} and Harmsen, {William S.} and Habermann, {Elizabeth B} and Shah, {Harsh N.} and Jakub, {James W}",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/jso.24649",
language = "English (US)",
volume = "116",
pages = "213--219",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy

AU - Murphy, Brittany L.

AU - Gonzalez, Alexandra B.

AU - Conners, Amy L.

AU - Henrichsen, Tara L.

AU - Keeney, Michael G.

AU - Chen, Beiyun

AU - Nguyen, Toan T.

AU - Harmsen, William S.

AU - Habermann, Elizabeth B

AU - Shah, Harsh N.

AU - Jakub, James W

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background and Objectives: Current randomized controlled trials are investigating the outcomes of non-surgical treatment for patients with ductal carcinoma in situ (DCIS). We sought to evaluate pre-operative factors associated with no residual disease at definitive resection following a core needle biopsy (CNB) diagnosis of DCIS. Methods: Eight hundred and thirty-four operations for DCIS were performed at our institution between January 2004 and October 2014. We evaluated patient and biopsy tumor characteristics to determine pre-operative factors associated with no residual disease at surgical resection using uni- and multivariable analyses. Results: Sixty-nine patients (8%) had no residual disease on final pathology. On multivariable analysis, low- or intermediate-grade lesions, <1 cm in size on mammography, and lesions where ≥90% of calcifications were removed correlated with finding no residual disease on final pathology, c-statistic 0.84. Of the 14 patients with all three low-risk factors, 36% had no residual disease on final pathology. Conclusions: Although our multivariable analysis performed well, its clinical utility would be limited as we were unable to identify a subset of patients with DCIS in whom the probability of finding no residual disease is low enough to consider routine use of non-surgical management.

AB - Background and Objectives: Current randomized controlled trials are investigating the outcomes of non-surgical treatment for patients with ductal carcinoma in situ (DCIS). We sought to evaluate pre-operative factors associated with no residual disease at definitive resection following a core needle biopsy (CNB) diagnosis of DCIS. Methods: Eight hundred and thirty-four operations for DCIS were performed at our institution between January 2004 and October 2014. We evaluated patient and biopsy tumor characteristics to determine pre-operative factors associated with no residual disease at surgical resection using uni- and multivariable analyses. Results: Sixty-nine patients (8%) had no residual disease on final pathology. On multivariable analysis, low- or intermediate-grade lesions, <1 cm in size on mammography, and lesions where ≥90% of calcifications were removed correlated with finding no residual disease on final pathology, c-statistic 0.84. Of the 14 patients with all three low-risk factors, 36% had no residual disease on final pathology. Conclusions: Although our multivariable analysis performed well, its clinical utility would be limited as we were unable to identify a subset of patients with DCIS in whom the probability of finding no residual disease is low enough to consider routine use of non-surgical management.

KW - core needle biopsy

KW - DCIS

KW - ductal carcinoma in situ

KW - invasive

KW - no residual disease

KW - progression

KW - upstage

UR - http://www.scopus.com/inward/record.url?scp=85018814285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018814285&partnerID=8YFLogxK

U2 - 10.1002/jso.24649

DO - 10.1002/jso.24649

M3 - Article

VL - 116

SP - 213

EP - 219

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -